Targeting VEGF for the Treatment of Colorectal Cancer
Phase III trial of IFL ± BV in MCRC study design
Survival
Bevacizumab plus chemotherapy in
1st
Line CRC
Adverse Events
IFL-related Adverse Events
2
nd
Line FOLFOX-4 ± BV (E3200) study design
E3200: overall survival
E3200: overall survival
TREE-1 and TREE-2
TREE-1 vs TREE-2 Response Rate
TREE-2 Grade 3/4 Toxicities
Possible BV-related Toxicity
GI Perforations in MCRC
Surgical wound healing complications
Bleeding complications during full dose anti- coagulation: IFL +/- BV
Arterial Thromboembolic Events in Trials of Bevacizumab + Chemotherapy
Arterial Thromboembolic Events (ATE) by Risk Group: Pooled Analysis
Conclusions
